WO2023020762A1 - Crystalline forms of tafamidis nicotinamide adduct - Google Patents

Crystalline forms of tafamidis nicotinamide adduct Download PDF

Info

Publication number
WO2023020762A1
WO2023020762A1 PCT/EP2022/070086 EP2022070086W WO2023020762A1 WO 2023020762 A1 WO2023020762 A1 WO 2023020762A1 EP 2022070086 W EP2022070086 W EP 2022070086W WO 2023020762 A1 WO2023020762 A1 WO 2023020762A1
Authority
WO
WIPO (PCT)
Prior art keywords
tafamidis
nicotinamide
adduct
solid
pattern
Prior art date
Application number
PCT/EP2022/070086
Other languages
French (fr)
Inventor
Michal HEGEDUS
Original Assignee
Synthon B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon B.V. filed Critical Synthon B.V.
Publication of WO2023020762A1 publication Critical patent/WO2023020762A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3

Definitions

  • the invention relates to Tafamidis nicotinamide adduct, a solid form thereof, a crystalline form thereof and processes for preparation thereof.
  • Tafamidis nicotinamide adduct, a solid form thereof, crystalline form thereof and processes for preparation thereof.
  • Tafamidis, compound of formula (1): chemically 2-(3,5-Dichlorophenyl)benzoxazole-6-carboxylic acid is a transthyretin protein stabilizer and antiamyloidogenic agent which was launched for the treatment of transthyretin amyloid polyneuropathy.
  • Tafamidis is marketed in a form of meglumine salt. Tafamidis was first disclosed in W02004056315 application. Polymorphic forms of Tafamidis are disclosed in W02016038500 or WO2019175263 applications.
  • Meglumine salt and solid form thereof is disclosed in WO2013038351 or WO2017190682 applications.
  • Tafamidis meglumine was first marketed in a 20 mg strength. Later studies demonstrated that a dose of 61 mg was more effective than the 20 mg dose, however the meglumine and other salts of Tafamidis had concentration depending gelling problems. The use of Tafamidis free acid solves this gelling problems. Unfortunately, the Tafamidis free acid has a lower solubility than meglumine Tafamidis salt.
  • tafamidis nicotinamide adduct according to presented invention overcomes the problems of the prior art (low solubility of Tafamidis free acid and gelling problems related to Tafamidis meglumine salt).
  • the presented invention relates to Tafamidis nicotinamide adduct, a solid form thereof, a crystalline form thereof and processes for preparation thereof.
  • Crystalline form of Tafamidis nicotinamide adduct of the presented invention shows improved solubility, crystallinity and stability in comparison with Tafamidis or Tafamidis meglumine solid forms disclosed in the prior art.
  • Figure 1 depicts the X-Ray Powder Diffractogram (XRPD) of crystalline Form 1 of Tafamidis nicotinamide adduct prepared according to Example lor Example 2 or Example 3.
  • XRPD X-Ray Powder Diffractogram
  • Figure 2 depicts the DSC pattern of crystalline Form 1 of Tafamidis nicotinamide adduct, Form 1 prepared according to Example lor Example 2 or Example 3.
  • Figure 3 depicts the TGA pattern of crystalline Form 1 of Tafamidis nicotinamide adduct prepared according to Example 1 or Example 2 or Example 3.
  • Figure 4 depicts the DSC pattern of crystalline form of Tafamidis meglumine salt prepared according to Example 1 of WO2013/038351A1 application.
  • Figure 5 depicts the NMR pattern of crystalline Form 1 of Tafamidis nicotinamide adduct prepared according to Example 1 or Example 2 or Example 3.
  • the presented invention relates to Tafamidis nicotinamide adduct, a solid form thereof, a crystalline form thereof and processes for preparation thereof.
  • the presented invention further relates to a formulation comprising the solid forms. Nicotinamide, chemically 3-pyridinecarboxamide is a compound of formula (2);
  • the crystalline form of Tafamidis nicotinamide adduct, Form 1 can be characterized by XRPD pattern having 20 values 7.0°, 11.8° and 13.0° degrees 2 theta ( ⁇ 0.2 degrees 2 theta).
  • the solid Form 1 can be also characterized by XRPD pattern having 20 values 7.0°, 11.8°, 13.0°, 19.6°, 25.2° and 26.7° degrees 2 theta ( ⁇ 0.2 degrees 2 theta).
  • the solid form can be further characterized by XRPD pattern described in the following table:
  • the solid Form 1 can be also characterized by XRPD pattern depicted in Figure 1 or
  • the solid Form 1 of Tafamidis, compound of formula (1) can be prepared by a process comprising: a. Dissolving Tafamidis in a solvent selected from tetrahydrofurane or dioxane; b. Adding nicotinamide; c. Isolating the crystalline Form 1 of Tafamidis nicotinamide adduct.
  • the concentration of Tafamidis in the solvent can be between 0.015 g/ml and 0.025 g/ml, preferably it is between 0.18 g/ml and 0.22 g/ml.
  • Tafamidis is preferably dissolved in the solvent at a temperature between 40°C and 65°C.
  • nicotinamide is added to the mixture.
  • the molar ratio between Tafamidis, compound of formula (1), and nicotinamide can be between 1:1 and 1:1.5, preferably it is between 1:1 and 1:1.2.
  • the mixture is stirred at a temperature between 40°C and 65°C to dissolve added nicotinamide and then stirred for between 10 and 30 minutes.
  • the mixture is the cooled to a temperature between 20°C and 25°C and it can be optionally filtered off.
  • the filtrate is then cooled to a temperature: i. Between 2-8°C in the case tetrahydrofurane is used as the solvent; or ii. Between 10°C and 15°C in the case dioxane is used as the solvent.
  • Obtained solid can be isolated by any suitable technique, for example by filtration and can be optionally dried to provide solid Form 1 of Tafamidis nicotinamide adduct.
  • the solid Form 1 of Tafamidis nicotinamide adduct can be also prepared by a process comprising:
  • the concentration of Tafamidis in methyl tert-butyl ether can be between 0.015 g/ml and 0.025 g/ml, preferably it is between 0.18 g/ml and 0.22 g/ml.
  • the molar ratio between Tafamidis and nicotinamide can be between 1:1 and 1:1.5, preferably it is between 1:1 and 1:1.2.
  • the mixture is stirred at a temperature between 20°C and 25°C for between 16 and 24 hours.
  • Obtained solid can be isolated by any suitable technique, for example by filtration and can be optionally dried to provide solid Form 1 of Tafamidis nicotinamide adduct.
  • Obtained solid form of Tafamidis nicotinamide adduct shows improved crystallinity, solubility and stability.
  • the solid form can be used for example for purification of Tafamidis, compound of formula (1) by contacting of Tafamidis nicotinamide adduct with a base.
  • the solid form according to presented invention can be also processed into a suitable pharmaceutical formulation.
  • the solid form can be mixed with pharmaceutically acceptable adjuvants, diluents or carriers.
  • the amount of solid form according to presented invention in the formulation depends on the condition and a patient to be treated.
  • the pharmaceutical formulation can be if form of a solid oral formulation, for example a capsule, a pill, a powder or a granule.
  • the crystalline form according to presented invention can be mixed with one or more additives such as fillers or extenders or binders or wetting agents or disintegrating agents or absorbents or lubricants or buffering agents.
  • the formulation in a form of a tablet or a dragee or a capsule or a pill or a granule can be coated with a coating or shell such as enteric or other coating.
  • the oral formulation can be in a form of an oral emulsion or a solution or a suspension or a syrup.
  • the formulation can contain suitable additives such as diluent(s) or wetting agent(s) or emulsifying agent(s) or suspending agent(s) or sweetening agent(s) or flavouring agent(s).
  • suitable additive(s) are known to those skilled in the art.
  • the suitable pharmaceutical formulation can be in a parenteral form such as an injection or an infusion or an injectable depot or in a liposomal form comprising pharmaceutically acceptable aqueous or non-aqueous solution(s) or dispersion(s) or emulsions.
  • the pharmaceutical formulation can be also in a form of a powder for reconstitution into an injection or infusion.
  • the formulation can further comprise additives such as preservative(s) or wetting agent(s) or emulsifying agent(s) or dispersing agent(s) or antibacterial or antifungal agents.
  • suitable additive(s) are known to those skilled in the art.
  • the suitable pharmaceutical formulation can be in a form suitable for rectal or vaginal administration further comprising suitable additive(s).
  • suitable additive(s) are known to those skilled in the art.
  • Tafamidis nicotinamide adduct or a solid form thereof for example Form 1 or a pharmaceutical formulation comprising the form can be used for the treatment of conditions treatable with Tafamidis or a salt thereof.
  • DCS patterns were obtained using the following conditions: 10°C/min -> 250°C.
  • Tafamidis was prepared according to a process disclosed in W02004056315.
  • Tafamidis meglumine salt was prepared according to Example 1 of WO2013/038351A1 application.
  • Tafamidis 1 g was mixed with 50 ml of tetrahydrofurane (THF). The formed suspension was mechanically stirred and heated to 50°C. 396 mg of nicotinamide was then added to the mixture. The mixture was stirred at 50°C till dissolution of solids. The mixture was then stirred at 50°C for 20 minutes. After, the solution was left freely cool down to room temperature (20-25°C), filtered to remove any undissolved solids, and placed into a refrigerator at temperature of 2-8 °C for 12 hours. The solid mass was filtered off to provide
  • Tafamidis nicotinamide adduct Form 1, in 76% yield.
  • XRPD pattern of obtained solid corresponds to a pattern depicted in Figure 1.
  • DSC pattern of obtained solid is depicted in Figure 2
  • TGA pattern is depicted in Figure 3
  • NMR pattern is depicted in Figure 5.
  • Tafamidis 1 g was mixed with 50 ml of dioxane. The formed suspension was mechanically stirred and heated to 55°C. 396 mg of nicotinamide was then added to the mixture. The mixture was stirred at 55°C till dissolution of solids. The mixture was then stirred at 55°C for 20 minutes. After, the solution is left freely cool down to room temperature (20-25°C), filtered to remove any undissolved solids. The mixture is then cooled to 13°C and left at this temperature for 12 hours. The solid mass was filtered off to provide Tafamidis nicotinamide adduct, Form 1, in yield 60%.
  • XRPD pattern of obtained solid corresponds to a pattern depicted in Figure 1.
  • DSC pattern of obtained solid is depicted in Figure 2
  • TGA pattern is depicted in Figure 3
  • NMR pattern is depicted in Figure 5.
  • Sample preparations were placed into a stirring carousel at temperature +37 °C and 100 rpm and stirred. After 1 hour and 4 hours about 1 mL of each sample was taken and filtered through a 0.2 pm filter into a vial. One part of filtered sample was diluted in 1 : 1 ratio with the Solvent solution (to prevent precipitation in the autosampler) a transferred into a vial, second part of filtered sample was directly transferred into a vial. Both samples were measured by HPLC method. Because of no difference between results of diluted sample and directly measured sample, solubility results are given as average of these two measurements.

Abstract

The presented invention relates to Tafamidis nicotinamide adduct, solid form thereof, crystalline form thereof, processes for preparation thereof and a composition comprising it.

Description

P1765PC00
CRYSTALLINE FORMS OF TAFAMIDIS NICOTINAMIDE ADDUCT
The invention relates to Tafamidis nicotinamide adduct, a solid form thereof, a crystalline form thereof and processes for preparation thereof.
BACKGROUND OF THE PRESENT INVENTION
This invention relates to Tafamidis nicotinamide adduct, a solid form thereof, crystalline form thereof and processes for preparation thereof. Tafamidis, compound of formula (1):
Figure imgf000002_0001
chemically 2-(3,5-Dichlorophenyl)benzoxazole-6-carboxylic acid is a transthyretin protein stabilizer and antiamyloidogenic agent which was launched for the treatment of transthyretin amyloid polyneuropathy. Tafamidis is marketed in a form of meglumine salt. Tafamidis was first disclosed in W02004056315 application. Polymorphic forms of Tafamidis are disclosed in W02016038500 or WO2019175263 applications. Meglumine salt and solid form thereof is disclosed in WO2013038351 or WO2017190682 applications. Tafamidis meglumine was first marketed in a 20 mg strength. Later studies demonstrated that a dose of 61 mg was more effective than the 20 mg dose, however the meglumine and other salts of Tafamidis had concentration depending gelling problems. The use of Tafamidis free acid solves this gelling problems. Unfortunately, the Tafamidis free acid has a lower solubility than meglumine Tafamidis salt. The inventors have surprisingly found that the tafamidis nicotinamide adduct according to presented invention overcomes the problems of the prior art (low solubility of Tafamidis free acid and gelling problems related to Tafamidis meglumine salt). BRIEF DESCRIPTION OF THE INVENTION
The presented invention relates to Tafamidis nicotinamide adduct, a solid form thereof, a crystalline form thereof and processes for preparation thereof.
Crystalline form of Tafamidis nicotinamide adduct of the presented invention shows improved solubility, crystallinity and stability in comparison with Tafamidis or Tafamidis meglumine solid forms disclosed in the prior art.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 depicts the X-Ray Powder Diffractogram (XRPD) of crystalline Form 1 of Tafamidis nicotinamide adduct prepared according to Example lor Example 2 or Example 3.
Figure 2 depicts the DSC pattern of crystalline Form 1 of Tafamidis nicotinamide adduct, Form 1 prepared according to Example lor Example 2 or Example 3.
Figure 3 depicts the TGA pattern of crystalline Form 1 of Tafamidis nicotinamide adduct prepared according to Example 1 or Example 2 or Example 3.
Figure 4 depicts the DSC pattern of crystalline form of Tafamidis meglumine salt prepared according to Example 1 of WO2013/038351A1 application.
Figure 5 depicts the NMR pattern of crystalline Form 1 of Tafamidis nicotinamide adduct prepared according to Example 1 or Example 2 or Example 3.
DETAILED DESCRIPTION OF THE INVENTION
The presented invention relates to Tafamidis nicotinamide adduct, a solid form thereof, a crystalline form thereof and processes for preparation thereof. The presented invention further relates to a formulation comprising the solid forms. Nicotinamide, chemically 3-pyridinecarboxamide is a compound of formula (2);
Figure imgf000004_0001
The crystalline form of Tafamidis nicotinamide adduct, Form 1 can be characterized by XRPD pattern having 20 values 7.0°, 11.8° and 13.0° degrees 2 theta (± 0.2 degrees 2 theta). The solid Form 1 can be also characterized by XRPD pattern having 20 values 7.0°, 11.8°, 13.0°, 19.6°, 25.2° and 26.7° degrees 2 theta (± 0.2 degrees 2 theta). The solid form can be further characterized by XRPD pattern described in the following table:
Figure imgf000004_0002
The solid Form 1 can be also characterized by XRPD pattern depicted in Figure 1 or
DSC pattern depicted in Figure 2 or TGA pattern depicted in Figure 3 or NMR pattern depicted in Figure 5.
The solid Form 1 of Tafamidis, compound of formula (1), can be prepared by a process comprising: a. Dissolving Tafamidis in a solvent selected from tetrahydrofurane or dioxane; b. Adding nicotinamide; c. Isolating the crystalline Form 1 of Tafamidis nicotinamide adduct.
The concentration of Tafamidis in the solvent can be between 0.015 g/ml and 0.025 g/ml, preferably it is between 0.18 g/ml and 0.22 g/ml. Tafamidis is preferably dissolved in the solvent at a temperature between 40°C and 65°C. After dissolution of Tafamidis, nicotinamide is added to the mixture. The molar ratio between Tafamidis, compound of formula (1), and nicotinamide can be between 1:1 and 1:1.5, preferably it is between 1:1 and 1:1.2. The mixture is stirred at a temperature between 40°C and 65°C to dissolve added nicotinamide and then stirred for between 10 and 30 minutes. The mixture is the cooled to a temperature between 20°C and 25°C and it can be optionally filtered off. The filtrate is then cooled to a temperature: i. Between 2-8°C in the case tetrahydrofurane is used as the solvent; or ii. Between 10°C and 15°C in the case dioxane is used as the solvent.
The mixture is left at this temperature for between 6 and 24 hours. Obtained solid can be isolated by any suitable technique, for example by filtration and can be optionally dried to provide solid Form 1 of Tafamidis nicotinamide adduct.
The solid Form 1 of Tafamidis nicotinamide adduct can be also prepared by a process comprising:
1. Mixing Tafamidis with nicotinamide and methyl tert-butyl ether (MTBE); 2. Stirring the mixture at a temperature between 20°C and 25°C for between 16 and
24 hours;
3. Isolating the solid Form 1 of Tafamidis nicotinamide adduct.
The concentration of Tafamidis in methyl tert-butyl ether can be between 0.015 g/ml and 0.025 g/ml, preferably it is between 0.18 g/ml and 0.22 g/ml. The molar ratio between Tafamidis and nicotinamide can be between 1:1 and 1:1.5, preferably it is between 1:1 and 1:1.2. The mixture is stirred at a temperature between 20°C and 25°C for between 16 and 24 hours. Obtained solid can be isolated by any suitable technique, for example by filtration and can be optionally dried to provide solid Form 1 of Tafamidis nicotinamide adduct.
Obtained solid form of Tafamidis nicotinamide adduct shows improved crystallinity, solubility and stability. The solid form can be used for example for purification of Tafamidis, compound of formula (1) by contacting of Tafamidis nicotinamide adduct with a base.
The solid form according to presented invention, preferably Form 1, can be also processed into a suitable pharmaceutical formulation. In the pharmaceutical formulation the solid form can be mixed with pharmaceutically acceptable adjuvants, diluents or carriers. The amount of solid form according to presented invention in the formulation depends on the condition and a patient to be treated. The pharmaceutical formulation can be if form of a solid oral formulation, for example a capsule, a pill, a powder or a granule. In the formulation the crystalline form according to presented invention can be mixed with one or more additives such as fillers or extenders or binders or wetting agents or disintegrating agents or absorbents or lubricants or buffering agents. The formulation in a form of a tablet or a dragee or a capsule or a pill or a granule can be coated with a coating or shell such as enteric or other coating. The oral formulation can be in a form of an oral emulsion or a solution or a suspension or a syrup. The formulation can contain suitable additives such as diluent(s) or wetting agent(s) or emulsifying agent(s) or suspending agent(s) or sweetening agent(s) or flavouring agent(s). The examples of suitable additive(s) are known to those skilled in the art.
The suitable pharmaceutical formulation can be in a parenteral form such as an injection or an infusion or an injectable depot or in a liposomal form comprising pharmaceutically acceptable aqueous or non-aqueous solution(s) or dispersion(s) or emulsions. The pharmaceutical formulation can be also in a form of a powder for reconstitution into an injection or infusion. The formulation can further comprise additives such as preservative(s) or wetting agent(s) or emulsifying agent(s) or dispersing agent(s) or antibacterial or antifungal agents. The examples of suitable additive(s) are known to those skilled in the art.
The suitable pharmaceutical formulation can be in a form suitable for rectal or vaginal administration further comprising suitable additive(s). The examples of suitable additive(s) are known to those skilled in the art.
Tafamidis nicotinamide adduct or a solid form thereof, for example Form 1 or a pharmaceutical formulation comprising the form can be used for the treatment of conditions treatable with Tafamidis or a salt thereof.
The invention will be further described with reference to the following examples.
EXAMPLES
Nuclear magnetic resonance spectroscopy (NMR) was performed using Avance III 400 MHz NMR spectrometer. XRPD spectrum was obtained using the following measurement conditions:
Panalytical Empyrean diffractometer with 0/20 geometry (transmition mode), equipped with a PixCell 3D detector;
Figure imgf000008_0001
DCS patterns were obtained using the following conditions: 10°C/min -> 250°C.
TGA patterns were obtained using the following conditions: 10°C/min -> 280°C. Tafamidis was prepared according to a process disclosed in W02004056315. Tafamidis meglumine salt was prepared according to Example 1 of WO2013/038351A1 application.
Example 1: Preparation of Tafamidis nicotinamide adduct, Form 1
1 g of Tafamidis was mixed with 50 ml of tetrahydrofurane (THF). The formed suspension was mechanically stirred and heated to 50°C. 396 mg of nicotinamide was then added to the mixture. The mixture was stirred at 50°C till dissolution of solids. The mixture was then stirred at 50°C for 20 minutes. After, the solution was left freely cool down to room temperature (20-25°C), filtered to remove any undissolved solids, and placed into a refrigerator at temperature of 2-8 °C for 12 hours. The solid mass was filtered off to provide
Tafamidis nicotinamide adduct, Form 1, in 76% yield.
XRPD pattern of obtained solid corresponds to a pattern depicted in Figure 1. DSC pattern of obtained solid is depicted in Figure 2, TGA pattern is depicted in Figure 3 and NMR pattern is depicted in Figure 5.
Example 2: Preparation of Tafamidis nicotinamide adduct, Form 1
1 g of Tafamidis was mixed with 50 ml of dioxane. The formed suspension was mechanically stirred and heated to 55°C. 396 mg of nicotinamide was then added to the mixture. The mixture was stirred at 55°C till dissolution of solids. The mixture was then stirred at 55°C for 20 minutes. After, the solution is left freely cool down to room temperature (20-25°C), filtered to remove any undissolved solids. The mixture is then cooled to 13°C and left at this temperature for 12 hours. The solid mass was filtered off to provide Tafamidis nicotinamide adduct, Form 1, in yield 60%.
XRPD pattern of obtained solid corresponds to a pattern depicted in Figure 1. DSC pattern of obtained solid is depicted in Figure 2, TGA pattern is depicted in Figure 3 and NMR pattern is depicted in Figure 5.
Example 3: Preparation of Tafamidis nicotinamide adduct, Form 1
1 g of Tafamidis and 396 mg of nicotinamide was mixed with 50 ml of methyl tertbutyl ether (MTBE). The formed suspension was mechanically stirred at a temperature between 20°C and 25°C for 18 hours. The solid mass was filtered off to provide Tafamidis nicotinamide adduct, Form 1, in almost quantitative yield. XRPD pattern of obtained solid corresponds to a pattern depicted in Figure 1. DSC pattern of obtained solid is depicted in Figure 2, TGA pattern is depicted in Figure 3 and NMR pattern is depicted in Figure 5. Example 4: Comparative example 1, solubility of samples
Solubility of Tafamidis nicotinamide adduct, Form 1 was compared to Tafamidis and Tafamidis meglumine salt.
Sample preparations were placed into a stirring carousel at temperature +37 °C and 100 rpm and stirred. After 1 hour and 4 hours about 1 mL of each sample was taken and filtered through a 0.2 pm filter into a vial. One part of filtered sample was diluted in 1 : 1 ratio with the Solvent solution (to prevent precipitation in the autosampler) a transferred into a vial, second part of filtered sample was directly transferred into a vial. Both samples were measured by HPLC method. Because of no difference between results of diluted sample and directly measured sample, solubility results are given as average of these two measurements.
Figure imgf000010_0001
It can be concluded that solubility of Tafamidis nicotinamide adduct is higher than solubility of Tafamidis free acid and comparable to solubility of Tafamidis meglumine, Form 1. Example 5: Comparative example 1, thermal stability of samples
DSC pattern of Tafamidis nicotinamide adduct, Form 1 and Tafamidis meglumine salt were measured. Obtained pattern are depicted in Figures 2 and 4. It can be concluded that thermal stability of Tafamidis nicotinamide adduct, Form 1, is higher than thermal stability of Tafamidis meglumine salt.

Claims

CLAIMS Tafamidis nicotinamide adduct. A solid form of compound according to claim 1. A crystalline form of compound according to claim 1, Form 1, characterized by XRPD pattern having 20 values 7.0°, 11.8° and 13.0° degrees 2 theta (± 0.2 degrees 2 theta). The crystalline form according to claim 3 characterized by XRPD pattern having 20 values 7.0°, 11.8°, 13.0°, 19.6°, 25.2° and 26.7° degrees 2 theta (± 0.2 degrees 2 theta). A process for preparation of the solid form according to claims 3 or 4 the process comprising: a. Dissolving Tafamidis in a solvent selected from tetrahydrofurane or dioxane; b. Adding nicotinamide; c. Isolating the crystalline Form 1 of Tafamidis nicotinamide adduct. A process for preparation of the solid form according to claims 3 or 4 the process comprising: a. Mixing Tafamidis with nicotinamide and methyl tert-butyl ether (MTBE); b. Stirring the mixture at a temperature between 20°C and 25°C for between
16 and 24 hours; c. Isolating the crystalline Form 1 of Tafamidis nicotinamide adduct.
PCT/EP2022/070086 2021-08-16 2022-07-18 Crystalline forms of tafamidis nicotinamide adduct WO2023020762A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21191557 2021-08-16
EP21191557.4 2021-08-16

Publications (1)

Publication Number Publication Date
WO2023020762A1 true WO2023020762A1 (en) 2023-02-23

Family

ID=77367269

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2022/070086 WO2023020762A1 (en) 2021-08-16 2022-07-18 Crystalline forms of tafamidis nicotinamide adduct

Country Status (1)

Country Link
WO (1) WO2023020762A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056315A2 (en) 2002-12-19 2004-07-08 The Scripps Research Institute Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2013038351A1 (en) 2011-09-16 2013-03-21 Pfizer Inc. Solid forms of a transthyretin dissociation inhibitor
WO2016038500A1 (en) 2014-09-08 2016-03-17 Pfizer Inc. Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
WO2017190682A1 (en) 2016-05-05 2017-11-09 苏州晶云药物科技有限公司 Crystalline form e of tafamidis methylglucamine salt, and preparation method and application thereof
WO2019175263A1 (en) 2018-03-13 2019-09-19 Azad Pharma Ag New polymorphs and new path to synthesize tafamidis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056315A2 (en) 2002-12-19 2004-07-08 The Scripps Research Institute Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2013038351A1 (en) 2011-09-16 2013-03-21 Pfizer Inc. Solid forms of a transthyretin dissociation inhibitor
WO2016038500A1 (en) 2014-09-08 2016-03-17 Pfizer Inc. Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
WO2017190682A1 (en) 2016-05-05 2017-11-09 苏州晶云药物科技有限公司 Crystalline form e of tafamidis methylglucamine salt, and preparation method and application thereof
WO2019175263A1 (en) 2018-03-13 2019-09-19 Azad Pharma Ag New polymorphs and new path to synthesize tafamidis

Similar Documents

Publication Publication Date Title
US8217061B2 (en) Polymorphs of sorafenib tosylate and sorafenib hemi-tosylate, and processes for preparation thereof
US11746109B2 (en) Crystalline forms of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate
JP5687291B2 (en) Crystalline salt of potent HCV inhibitor
WO2017008773A1 (en) Crystalline forms of obeticholic acid
CN110922403B (en) Co-crystal formed by apixaban and carboxylic acid and preparation method thereof
JP6691218B2 (en) Novel crystalline form of selective S1P1 receptor agonist and method for producing the same
US20220348543A1 (en) Salts of omecamtiv mecarbil and solid forms thereof
WO2014152763A1 (en) Cephalosporin compositions and methods of manufacture
US20220340542A1 (en) Salts of omecamtiv mecarbil and solid forms thereof
WO2016127963A1 (en) Solid forms of palbociclib salts
CN103193864B (en) Delta crystalline form of the arginine salt of perindopril, a process for its preparation, and pharmaceutical compositions containing it
WO2023020762A1 (en) Crystalline forms of tafamidis nicotinamide adduct
US20230036336A1 (en) Crystalline forms of sodium salt of bempedoic acid
WO2021255180A1 (en) Salts of bempedoic acid
CN110903239A (en) Novel crystal form of lenvatinib mesylate and preparation method thereof
JP5628816B2 (en) Choline and tromethamine salts of lycoferon
US20120208787A1 (en) Crystalline form of fosamprenavir calcium
CN112409380A (en) Preparation method and application of novel crystal form of bicarvir sodium
WO2021064166A1 (en) Crystalline forms of bempedoic acid
CN114133378B (en) Nilotinib hydrochloride eutectic and preparation method thereof
KR20190029601A (en) Solid form of TTK inhibitor
US20210017181A1 (en) Pyridine or n,n-dimethyl acetamide solvated solid state forms of solvated idelalisib, their use and preparation
KR102026337B1 (en) Novel 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine salt and method for preparing the same
WO2023194300A1 (en) Solid forms of vismodegib
CZ2018466A3 (en) Solid forms of ozanimod and their preparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22751097

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE